Business Wire News Releases | Owen Sound Sun Times

Business Wire News Releases

Bluma Wellness Announces Proposed Warrant Repricing and Redemption of Debentures

TORONTO — Bluma Wellness Inc. (the “ Company ”) (CSE: BWEL.U) (OTCQX:BMWLF) announces today that it proposes to amend the exercise price of up to 45,869,475 common share purchase warrants of the Company (collectively, the “ Warrants ”) to a price of US$1.01 per common share in the capital of the Company (each a “ Common Share ”), representing the closing price of the Common Shares on the Canadian Securities Exchange (the “ CSE ”) on January 14, 2021 (the “ Repricing ”). The Warrants were issued on various dates between June 26, 2020 and October 30, 2020, in connection with the conversion of the outstanding principal and accrued interest on the then issued and outstanding 12.5% unsecured convertible debentures of the Company (“ 12.5% Debentures ”) in accordance with their terms. The Warrants are currently exercisable for a period of two years from the date of issuance into Common Shares at an exercise price per Common Share currently equal to the greater of: (i) US$1.00; (ii) the volume weighted average price at which the Common Shares have traded on the CSE during the five trading days ending on the date of exercise; and (iii) 110% of the price at which the 12.5% Debentures were converted. No other terms of the Warrants will be amended other than for fixing their exercise price at US$1.01. Completion of the Repricing is subject to approval of the CSE and the unanimous approval of the holders of the Warrants.

1 hour ago Business Wire News Releases
Image by default
Business Wire News Releases

Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021 VANCOUVER, British Columbia — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma (GEA). The data are being presented today at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually January 15 – 17, 2021.

1 hour ago Business Wire News Releases
Image by default

Latest Videos

 
 
 
 

Up Next

  1.  
  2.  
  3.  
  4.  
  5.  

Advertisement

Stories continue below
This advertisement has not loaded yet, but your article continues below.

weather (Owen Sound)

Advertisement

Stories continue below
This advertisement has not loaded yet, but your article continues below.

Around the Network

Contests

Advertisement

Stories continue below
This advertisement has not loaded yet, but your article continues below.

Advertisement

Stories continue below
This advertisement has not loaded yet, but your article continues below.